703-51-5

Usage

Uses

Used in Pharmaceutical Research:
3,4-Dihydro-1,4-benzoxazepin-5(2H)-one is utilized as a subject of research for its potential as an anticonvulsant and anxiolytic agent, given its unique chemical structure and pharmacological properties. 3,4-Hihydro-1,4-benzoxazepin-5(2H)-one's ability to modulate neurological responses makes it a promising candidate for the development of new medications aimed at treating epilepsy and anxiety disorders.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3,4-Dihydro-1,4-benzoxazepin-5(2H)-one serves as a valuable compound for drug development. Its structure and properties are being explored to design and synthesize new drugs that could address a range of medical conditions, particularly those related to the central nervous system.
Used in Neurological Applications:
3,4-Hihydro-1,4-benzoxazepin-5(2H)-one is used as a potential therapeutic agent in neurological applications, specifically for conditions that involve seizures and anxiety. Its pharmacological profile suggests that it may have a calming effect on the nervous system, which could be beneficial in managing the symptoms of epilepsy and anxiety disorders.

InChI:InChI=1/C9H9NO2/c11-9-7-3-1-2-4-8(7)12-6-5-10-9/h1-4H,5-6H2,(H,10,11)

Upstream product

• 24541-01-3 chroman-4-one oxime 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 

Downstream Products

• 708-05-4 4-methyl-6,7-benzo-1-ox-4-azepin-5-one 
• 784983-95-5 (aminoethoxy)benzoic acid 
• 21228-44-4 3,4-dihydro-2H-benzo[f][1,4]oxazepine-5-thione 
• 5755-05-5 7-bromo-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one 
• 30558-92-0 benzyl-(2,3-dihydro-benzo[f][1,4]oxazepin-5-yl)-amine; hydrochloride 
• 30786-16-4 4-(4-chloro-benzyl)-3,4-dihydro-2H-benzo[f][1,4]oxazepine-5-thione 
• 919091-52-4 5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepine-7-sulfonyl chloride 
• 554-68-7 triethylamine hydrochloride 
• 1251156-08-7 [7-(6-aminopyridin-3-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)-phenyl]methanone 
• 740842-71-1 7-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine 
• 17775-01-8 2.3.4.5-Tetrahydro-benzo[f][1,4]oxazepine 
• 740842-73-3 1,1-dimethylethyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 
• 1443211-72-0 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one 
• 1430092-39-9 C₁₆H₁₂F₃NO₃ 

Relevant academic research and scientific papers

Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan

A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D 2 and α1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]- 1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.

Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N- methyltransferase

In the search for potent and selective inhibitors of the enzyme phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), we examined the effect of ring size or an additional heteroatom in the conformationally- restricted benzylamine-type PNMT inhibitors. Based on semiempirical calculations (MNDO) and molecular modeling studies, PNMT-inhibitory activity of these compounds seemed to be dependent on (a) the torsion angle between the plane of the aromatic ring and the endo N atom lone pair (τ2 angle), with the optimal value of τ2 being about -75°, and (b) the amount of steric bulk about the 3-position of 1,2,3,4-tetrahydroisoquinoline (5, THIQ). 2,3,4,5-Tetrahydro-1H-2-benzazepine (6) was found to have the highest selectivity (PNMT K(i) = 3.34 μM, α2 K(i) = 11 μM, selectivity = 3.2) as compared to other homologues of THIQ (PNMT K(i) = 9.67 μM, α2 K(i) = 0.35 μM, selectivity = 0.036). The higher PNMT-inhibitory activity of 6 was attributed to favorable steric interactions of the puckered methylene groups in the putative bioactive conformation of 6 at the PNMT active site, whereas unfavorable interactions of these puckered methylene groups at the α2- adrenoceptor were thought to be the cause of reduced α2 affinity of 6. No further enhancement of the selectivity of the benzazepine ring system could be obtained via introduction of a second heteroatom (N, O, S) at the 5- position in this ring system.